Imatinib

ATC Code L01EA01

Imatinib

Definition

An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.

Also known as 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, IMATINIB — per NCIT

Also identified as

Indications

Disease Relation Source
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive may treat MEDRT · Public domain (U.S. Government work)
Dermatofibrosarcoma protuberans may treat MEDRT · Public domain (U.S. Government work)
Digestive system neoplasm may treat MEDRT · Public domain (U.S. Government work)
Hypereosinophilic syndrome may treat MEDRT · Public domain (U.S. Government work)
Leukemia, myeloid, accelerated-phase may treat MEDRT · Public domain (U.S. Government work)
Lymphoid leukemia may treat MEDRT · Public domain (U.S. Government work)
Myelodysplastic/myeloproliferative disease may treat MEDRT · Public domain (U.S. Government work)
Myeloid leukemia may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Bone marrow may treat a disease of this organ DERIVED · CC BY 4.0
Dermis may treat a disease of this organ DERIVED · CC BY 4.0
Lymphoid system may treat a disease of this organ DERIVED · CC BY 4.0
Skin of body may treat a disease of this organ DERIVED · CC BY 4.0

4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.